Psychedelic Research and Access in
Uruguay
Uruguay has a small visible psychedelic ecosystem in Blossom, with one linked stakeholder and no country-linked psychedelic clinical trials. The page should therefore be read as a cautious regulatory and ecosystem note rather than evidence of a developed psychedelic research market.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inUruguay.
- 1
Blossom currently links Uruguay to one psychedelic stakeholder and no country-linked psychedelic clinical trials.
- 2
The strongest official signal is controlled-substances regulation rather than liberalised psychedelic access.
- 3
Ayahuasca and related observational or surveillance signals are relevant context but should not be presented as a registered treatment pathway.
- 4
Ketamine and DMT-related surveillance mentions indicate public-health monitoring, not necessarily sanctioned therapeutic access.
- 5
Future updates should prioritise Ministry of Public Health, controlled-substance schedule, clinical-registry, and university sources.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Uruguay, but the page does include 3 stakeholders.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 3
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Uruguay maintains a conventional controlled-substances approach to classic and novel psychedelics: most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, ibogaine, ayahuasca) are treated under national drug control schemes with no routine reimbursed medical programs; ketamine is an accepted medical/veterinary anesthetic and is used off-label in some private clinical settings for psychiatric indications. There is active public debate, some private/'grey-area' practice and interest from clinicians/entrepreneurs, but no broad public...
Regulatory Status
Uruguay appears to retain a conventional controlled-substances approach for classic psychedelics. Ministry of Public Health materials list the national framework for narcotics, psychotropics, precursors, and controlled chemicals, while separate cannabis rules should not be generalised to psychedelics. The lightweight review did not identify a routine authorised pathway for psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, or ayahuasca as medical treatments; any access claim should distinguish surveillance, cultural or private practice signals from regulated clinical availability.
Country Details
- Region
- South America
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
Uruguay maintains a conventional controlled-substances approach to classic and novel psychedelics: most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, ibogaine, ayahuasca) are treated under national drug control schemes with no routine reimbursed medical programs...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Uruguay.
Open scorecard →Psychedelic Stakeholders in Uruguay
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Uruguay.